Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

http://www.businessweek.com/news/2013-05-01/allergan-evaluates-bids-for-its-lap-band-weight-loss-product

Bloomberg News

Allergan Shares Fall After CEO Says Drug Trial Will Be Delayed

May 01, 2013

Allergan Inc. (AGN:US), the maker of the Botox wrinkle treatment, fell as much as 14 percent after saying it will delay further study of an experimental drug for age-related macular degeneration. Regeneron Pharmaceuticals Inc., which makes potential rival eye medicine Eylea, surged.

Allergan tumbled 9.1 percent to $103.19 at 11:23 a.m. New York time, after declining to $98 in the biggest intraday drop since November 2008.

David Pyott, the chief executive of Irvine, California- based Allergan, said on a conference call today that current data don’t support taking the medicine into the final stages of trials needed for regulatory approval.

Regeneron jumped as much as 17 percent, and gained 12 percent to $240.79.

To contact the reporters on this story: Sasha Damouni in New York at sdamouni2@bloomberg.net; Clyde Eltzroth in New York at celtzroth1@bloomberg.net

To contact the editor responsible for this story: Joanna Ossinger at jossinger@bloomberg.net; Reg Gale at rgale5@bloomberg.net


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus